Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 1/20 | 0.45 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.34 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9187434 | 0.83 | GRIN2D (0.37) | SLC22A2SLC47A1MAPTALDH1A1NPC1 | |
| SCHEMBL3718473 | 0.78 | SLC22A2 (0.38) | SLC22A2SLC47A1MAPTALDH1A1NPC1 | |
| SCHEMBL6031488 | 0.74 | — | — | |
| SCHEMBL27651884 | 0.71 | SLC22A2 (0.50) | SLC22A2SLC47A1MAPTALDH1A1NPC1 | |
| SCHEMBL237472 | 0.67 | SLC22A2 (0.56) | SLC22A2SLC47A1MAPTALDH1A1NPC1 | |
| SCHEMBL6655788 | 0.67 | SLC22A2 (0.56) | SLC22A2SLC47A1MAPTALDH1A1NPC1 | |
| SCHEMBL677940 | 0.66 | SLC22A2 (0.62) | SLC22A2SLC47A1MAPTALDH1A1NPC1 | |
| SCHEMBL455611 | 0.66 | SLC22A2 (0.62) | SLC22A2SLC47A1MAPTALDH1A1NPC1 | |
| SCHEMBL138375 | 0.66 | SLC22A2 (0.62) | SLC22A2SLC47A1MAPTALDH1A1NPC1 | |
| SCHEMBL28190940 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092039-A1 | DUAL INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | UNIV BARCELONA (ES) | 2026-04-02 | — | — | US | disclosed |
| EP-4676916-A1 | DUAL INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Universitat De Barcelona (ES) | 2026-01-14 | — | — | EP | disclosed |
| WO-2024184305-A1 | DUAL INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | UNIVERSITAT DE BARCELONA (ES) | 2024-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092039-A1 | DUAL INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE2, BACE1, GLS2 | SLC22A2 828/4885SLC47A1 371/4885MAPT 1205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.